Skip to main content

Table 2 Ring-stage survival assay percent survival values from drug treated artemisinin-resistant and artemisinin-sensitive parasites

From: Retargeting azithromycin analogues to have dual-modality antimalarial activity

Modification Compound Cam3.IIsensitive 72 hr growth IC50 (μM, ±SEM) Cam3.IIresistant 72 hr growth IC50 (μM, ±SEM) Concentration of drug = 5% growth of Cam3.IIsensitive (μM) Growth Cam3.IIDHA resistant(R539T) (%)
  DHA 0.007 (0.002) 0.011 (0.001) 0.05 41
  Azithromycin 30 (5.5) 30 (0.005) 100 1
Naphthalene 3 0.035 (0.004) 0.04 (0.004) 0.4 8
2-Chlorophenyl 5 0.2 (0.02) 0.28 (0.005) 0.5 6
7-Chloroquinoline 56 0.004 (0.001) 0.009 (0.001) 0.055 7
Quinolone 71 0.07 (0.007) 0.15 (0.03) 0.6 6
  1. The μM concentration of drug (DHA, azithromycin, GSK-3, GSK-5, GSK-56 and GSK-71) that resulted in a 5% survival value for artemisinin-sensitive Cam3.IIsensitive parasites was then used to treat artemisinin-resistant Cam3.IIDHA resistant(R539T) parasites, and the resulting % parasite survival value for the resistant parasites is displayed in the table. The IC50 value of the drugs against Cam3.IIsensitive and Cam3.IIresistant strains is also shown to indicate their overall potency against artemisinin-sensitive and artemisinin-resistant parasites. Parasites were incubated for one cycle (72 hrs) after pulsed drug treatment and washing prior to measurement of parasitaemia by flow cytometry. Data represent the mean of 2 experiments